Share-based Payment Arrangement, Expense of Tarsus Pharmaceuticals, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tarsus Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Tarsus Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $12,243,000, a 65% increase year-over-year.
  • Tarsus Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $34,810,000, a 34% increase year-over-year.
  • Tarsus Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $27,818,000, a 40% increase from 2023.
  • Tarsus Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $19,830,000, a 47% increase from 2022.
  • Tarsus Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $13,460,000, a 59% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Tarsus Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $34,810,000 $12,243,000 +$4,828,000 +65% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $29,982,000 $8,234,000 +$753,000 +10% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $29,229,000 $6,930,000 +$1,411,000 +26% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $27,818,000 $7,403,000 +$1,921,000 +35% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $25,897,000 $7,415,000 +$2,165,000 +41% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $23,732,000 $7,481,000 +$2,289,000 +44% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $21,443,000 $5,519,000 +$1,613,000 +41% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $19,830,000 $5,482,000 +$1,811,000 +49% 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $18,019,000 $5,250,000 +$1,667,000 +47% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $16,352,000 $5,192,000 +$1,660,000 +47% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $14,692,000 $3,906,000 +$1,232,000 +46% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $13,460,000 $3,671,000 +$1,492,000 +68% 01 Oct 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
Q3 2022 $11,968,000 $3,583,000 +$1,464,000 +69% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $10,504,000 $3,532,000 +$738,000 +26% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $9,766,000 $2,674,000 +$1,311,000 +96% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $8,455,000 $2,179,000 +$5,736,000 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
Q3 2021 $2,719,000 $2,119,000 +$1,896,000 +850% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $823,000 $2,794,000 +$2,621,000 +1515% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $1,798,000 $1,363,000 -$2,637,000 -66% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $839,000 $3,557,000 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
Q3 2020 $223,000 +$218,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $173,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $4,000,000 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q3 2019 $5,000* 01 Jul 2019 30 Sep 2019 10-Q 25 Nov 2020 2020 Q3

Tarsus Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $27,818,000 +$7,988,000 +40% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $19,830,000 +$6,370,000 +47% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $13,460,000 +$5,005,000 +59% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $8,455,000 +$7,616,000 +908% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
2020 $839,000 +$821,000 +4561% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
2019 $18,000 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.